Antibacterial and anticancer activities of orphan biosynthetic gene clusters from Atlantis II Red Sea brine pool

Laila Ziko¹, Al-Hussein A. Saqr², Amged Ouf¹,², Matthias Gimpel³, Ramy K. Aziz⁴, Peter Neubauer³ and Rania Siam¹,²*

Abstract

Background: Cancer and infectious diseases are problematic because of continuous emergence of drug resistance. One way to address this enormous global health threat is bioprospecting the unlikeliest environments, such as extreme marine niches, which have tremendous biodiversity that is barely explored. One such environment is the Red Sea brine pool, Atlantis II Deep (ATII). Here, we functionally screened a fosmid library of metagenomic DNA isolated from the ATII lower convective layer (LCL) for antibacterial and anticancer activities.

Results: Selected clones, 14-7E and 10-2G, displayed antibacterial effects on the marine strain Bacillus sp. Cc6. Moreover, whole cell lysates from 14-7E and 10-2G exhibited decreased cell viability against MCF-7 (39.1% ± 6.6, 42% ± 8.1 at 50% v/v) and U2OS cells (35.7% ± 1.9, 79.9% ± 5.9 at 50% v/v), respectively. By sequencing the insert DNA from 14-7E and 10-2G, we identified two putative orphan biosynthetic gene clusters. Both clusters harbored putative ATP-binding cassette (ABC) transporter permeases and S-adenosylmethionine-related genes. Interestingly, the biosynthetic gene cluster identified on 14-7E is of archaeal origin and harbors a putative transcription factor. Several identified genes may be responsible for the observed antibacterial and anticancer activities. The 14-7E biosynthetic gene cluster may be encoding enzymes producing a specialized metabolite (effect of detected genes involved in C–C bond formation and glycosylation). The bioactivity may also be due to predicted subtilases encoded by this cluster. The 10-2G cluster harbored putative glycosyltransferase and non-ribosomal peptide synthase genes; thus the observed activity of this clone could be caused by a bioactive peptide.

Conclusions: The ATII LCL prokaryotic metagenome hosts putative orphan biosynthetic gene clusters that confer antibiotic and anticancer effects. Further biochemical studies should characterize the detected bioactive components, and the potential use of 14-7E metabolite for antibiosis and 10-2G metabolite as a selective anti-breast cancer drug.

Keywords: Atlantis II Red Sea brine pool, Antibacterial, Anticancer, Orphan biosynthetic gene clusters, Specialized metabolism

*Correspondence: rsiam@aucegypt.edu

¹ Graduate Program of Biotechnology, School of Sciences and Engineering, The American University in Cairo, New Cairo, Cairo 11835, Egypt

Full list of author information is available at the end of the article

© The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

Currently the healthcare sector is seriously challenged by a rapidly increasing inefficiency of antibacterial and anticancer drugs. The last years have been referred to as the resistance or post-antibiotic era, as increasing numbers of resistant microbial strains are detected to all or most of the available antimicrobials [1]. Recent reports of resistance to colistins, last-resort antimicrobial agents, are worrying [2]. Cancer treatment is facing a similar problem, as several cancers exhibit multi-drug resistance (MDR) against anticancer drugs [3]. Consequently, there is a need for new antimicrobial and anticancer drugs that could either surmount or bypass the MDR hurdle [3].

Nature is an inexhaustible reservoir of drugs against a wide spectrum of diseases [4]. Almost 73% of the FDA-approved small molecule antibiotics and 83% of the approved small molecule anticancer agents are either natural products, their derivatives or mimics [4]. Thus, mining nature for bioactive molecules has proven valuable in investigating diverse environmental niches, and will undoubtedly shed light on new chemistries with bioactivity, specifically antibiotics and anticancer effects [3–5]. Interestingly, since the early forties some antibiotic compounds have been known to also possess anticancer activity [6]. This group of anticancer antibiotics includes drugs of diverse chemical structures, such as bleomycin, actinomycin D and doxorubicin [6, 7].

Many microbes produce bioactive compounds, known as specialized metabolites, that are not involved in their primary basic activities [8, 9], but rather confer survival advantages to the hosts in their native environment [9]. For example, in marine environments, small molecules help microbes to survive in this competitive niche by quorum quenching or by antagonism [10]. Such specialized metabolites are encoded by an assortment of genes, often arranged in the host genome as biosynthetic gene clusters (BGCs) [9]. BGCs essentially comprise contiguous genes that together encode the production of one or more related specialized metabolites [9]. These clusters are required for the synthesis of a large spectrum of structurally diverse compounds such as polyketides and non-ribosomal peptides [9, 11]. BGCs comprise genes required for the synthesis of the specialized metabolites, as well as regulatory genes and genes that confer resistance to the host against its own metabolites [9]. Computational mining for BGCs in microbial genomes can be conducted by a suite of tools, e.g. antiSMASH (the antibiotics and secondary metabolite analysis shell) [11, 12].

Microbes, the interaction of symbiotic microbes and their hosts, as well as free-living microbes in extreme conditions, all play key roles in producing new natural products of pharmacological importance [4]. Although earlier studies on microbes producing bioactive compounds were restricted to the few culturable organisms or ‘the low hanging fruits’ unculturable organisms became later on accessible by DNA sequence-based approaches [13]. Such high-throughput approaches increased our understanding of the complexity of marine microbiomes, particularly of extreme environments [13–15]. The biodiversity of biomes harboring thermophilic and marine niches is reported to be much higher than that of cultured organisms, and are thus considered hotspots to look for novel microbes and bioactive compounds [13].

Many compounds isolated from marine bacteria were effective against antibiotic-resistant strains [16]. One example is 1-acetyl-β-carboline, isolated from a *Streptomyces* species inhabiting a shallow marine sediment in Korea was effective against methicillin-resistant *Staphylococcus aureus* (MRSA) strains [16, 17]. Another example is salinilactam, that was discovered by mining the genome of the marine actinomycete *Salinispora tropica* and was found to have an antibacterial effect [18, 19]. Also, several marine products have been found to be useful in overcoming the MDR exhibited by cancer cells, such as sipholane triterpenoids isolated from the Red Sea sponge *Callyspongia siphonella*, that could overcome MDR and had anti-proliferative effects against breast cancer cell lines [3]. Another interesting example is salinosporamide K, an anticancer non-ribosomal peptide that was identified in the genome of the marine bacterium *Salinispora pacifica* [18, 20]. Several FDA-approved drugs were derived from natural products of marine origin, e.g. eribulin, a macrocyclic ketone analogue of halichondrin B that is used against metastatic breast cancer [21]. Caboxamycin, produced by a microbe living in the deep-sea sediment of the Canary basin, was active against several cancer cell lines, inhibited phosphodiesterase, and was active against several Gram-positive bacteria [22]. Until 2013, 578 natural products were isolated from deep sea inhabitants, including only 2 from Archaea and 123 from bacteria and fungi [21, 23].

Several compounds with a wide range of bioactivities were isolated from the Red Sea, that exhibit antiviral, antifungal and anti-oxidant activities [24]. The Red Sea hosts 25 deep hypersaline anoxic basins (DHABs) or brine pools [25, 26]. Extracts from microbiota inhabiting Red Sea brine pools (namely: Nereus brine, Kebrit sediment, and brine–seawater interface layers in Atlantis II, Kebrit Deep, Erba Deep, Nereus Deep and Discovery Deep), exhibited cytotoxic activity and in some cases apoptosis towards MCF-7, HeLa and DU1245 cancer cells [27, 28]. The deepest part of the Red Sea is the Atlantis II Deep Lower Convective Layer (ATII LCL), and ATII brine pool is 2194 m deep [25, 29]. It has multiple extreme conditions: high salinity (252 psu), high
temperature (~67.1 °C) and high heavy metal content [26, 30–32]. Several enzymes have been isolated from ATII LCL, such as a thermophilic esterase [33], a nitrilase [34] and two thermostable antibiotic resistance enzymes [35]. This study uses a culture-independent approach to investigate antibacterial and anticancer activities conferred by the metagenome of the ATII LCL niche. Also, bioinformatic analysis of assembled metagenomic reads from several Red Sea brine pools unraveled 524 specialized metabolism gene clusters in ATII LCL [36]. The computational detection of potential specialized metabolism gene clusters rooted for the experimental detection of specialized metabolites in samples from the same site.

Through functional screening of an ATII LCL metagenomic fosmid library, antibacterial activity and anticancer effects were assessed (Fig. 1). Sequencing and gene annotation of selected positive clones indicated potential antibacterial and anticancer activities of gene products. Accordingly, functionally screening extremophile metagenomes could be a valuable strategy to search for novel antibacterial and anticancer agents.

Results
Identification of antibacterial activity of Red Sea Atlantis II LCL fosmid library clones
Out of the 10,656 clones screened, 11 exhibited zones of inhibition, indicating antibacterial activity against Bacillus sp. Cc6. The largest inhibitory zones were generated by 14-7E (diameter of 1.6 cm) (Additional file 1: Figure S1-a), and 10-2G (diameter of 0.6 cm) (Fig. 2, Additional file 1: Figure S1-b1). Nine other clones also generated zones of inhibition. The positive control strain had an inhibitory zone of 0.7 cm (Additional file 1: Figure S1-b2). The diameters were measured from a single dish containing 96 clones (Additional file 1: Figure S1). For better visualization, 14-7E and the positive control were individually assessed on the same plate (Fig. 2a). Consequently, 14-7E and 10-2G were selected for further experimentation.

Differential decrease in cell viability by selected Red Sea Atlantis II LCL fosmid library extracts
Whole cell lysates were prepared from 14-7E and 10-2G, and the protein concentrations of the resulting extracts were determined to be 472.8 µg/ml and 642.8 µg/ml, for 14-7E and 10-2G respectively. The effect of the lysates on cell viability was tested on cancerous human breast adenocarcinoma (MCF-7) and bone osteosarcoma (U2OS) cell lines as well as the non-cancerous human telomerase reverse transcriptase immortalized cell line (1BR hTERT), for 48 h (Fig. 3a–c). Generally, a dose-dependent effect was observed, as less cell viability was detected with increasing lysate concentration (Additional file 1: Figure S3a–c). For MCF-7 cells, a similar and significant decrease in cell viability was observed upon addition of either 14-7E extracts (cell viability 39.1% ± 6.6; \( P \leq 0.05 \)) or 10-2G extracts (cell viability 42% ± 8.1; \( P \leq 0.05 \)) at 50% v/v. Compared to the buffer (cell viability 76.4% ± 9.6), addition of both extracts reduced cell viability about two-fold (Fig. 3a). In the case of U2OS cells, viability was only significantly decreased with the 14-7E extract (cell viability 35.7% ± 1.9; \( P \leq 0.001 \)), whereas the buffer control

---

**Fig. 1** Project workflow. DNA from ATII Red Sea brine pool Lower Convective Layer (LCL) was earlier isolated and a fosmid library was constructed containing 10,656 clones [33]. An anti-bacterial overlay assay was conducted to functionally screen for antibiotic activity. Clones that exhibited zones of inhibition were further sequenced and annotated. This was followed by extraction of whole cell lysates to assess cell viability against different cell lines.
(86.0% ± 15) and 10-2G extract (cell viability 79.9 ± 5.9; $P > 0.05$) affected cell viability only marginally at 50% v/v (Fig. 3b). As putative anti-cancer drugs should specifically target cancerous cells without affecting non-cancerous cells, we used the immortalized but non-cancerous 1BR hTERT cell line for the cell viability assay. At 50% v/v,
the buffer (71.6% ± 5.6) and 10-2G extract (76.4% ± 4.8; 
P > 0.05) induced only marginal decrease in cell viability, 
whereas cell viability decreased significantly again with 14-7E extract (48.1% ± 3.4; 
P ≤ 0.05) (Fig. 3c).

Annotation of the fosmid insert DNA in antibacterial 
and anticancer Red Sea Atlantis II LCL clones

Both fosmid clones (14-7E and 10-2G) were deeply 
sequenced (~ 30,000× and 1500× coverage respectively). 
The generated assembled reads, following quality control, 
generated 29 scaffolds for 14-7E, and 14 scaffolds for 
10-2G (Table 1). The number of protein-encoding genes 
(PEGs) detected by Rapid Annotations using Subsystems 
Technology (RAST) in each assembly was 289 and 30 
for 14-7E and 10-2G, respectively (Table 1). The major-
ity of PEGs encoded hypothetical proteins (90% of 14-7E 
PEGs and 84% of 10-2G PEGs) (Table 2, Additional file 1: 
Tables S1, S2).

To gain better understanding of the PEGs, including 
those encoding hypothetical proteins, we used two tools 
for further annotation: PSI-BLAST analysis against NCBI 
non-redundant protein database and BLASTX against 
curated sequences in Minimum Information about a 
Biosynthetic Gene cluster (MIBiG) database. The PSI-
BLAST analysis elaborated on the closest homolog of 
each PEG. PSI-BLAST was especially used because it is 
more powerful in detection of similarities between evo-

dutionary distant protein sequences [37]. On the other 
hand, the BLASTX/MIBiG analysis allowed the identi-
fication of the closest characterized biosynthetic gene 
cluster homolog of each PEG. The PSI-BLAST analysis 
allowed the annotation of some hypothetical proteins

| Table 1 Assembly metrics of the bioactive fosmid insert DNA from Red Sea ATII LCL |
|-------------------------------|-------------------------------|
| **Assembly statistics**        | **14-7E insert**              |
| Sequencing method             | Illumina HiSeq TruSeq DNA PCR Free (350) |
| De novo assembly program      | SOAPdenovo2                   |
| Total bases                   | 2,044,687,834                 |
| Total reads                   | 20,244,434                    |
| Total reads after quality filtering | 14,876,068                 |
| Total bases in scaffolds      | 201,086                       |
| Scaffold N50                  | 15,392                        |
| Number of scaffolds           | 29                            |
| Total bases in scaffolds after filtering and trimming | 201,086 |
| Scaffold N50 after filtering and trimming | 15,392                      |
| Number of scaffolds after filtering and trimming | 29                        |
| Number of scaffolds with RAST-annotated PEGs | 27                |
| Number of PEGs                | 289                           |
|-------------------------------|-------------------------------|
| **10-2G insert**              | Illumina MiSeq: 300 bp paired—end read (Illumina MiSeq V3) |
| De novo assembly program      | CLC Genomics Workbench v 8.0 |
| Total bases                   | 72,217,200                    |
| Total reads                   | 240,724                       |
| Total reads after quality filtering | 240,658                     |
| Total bases in scaffolds      | 2,452,525                     |
| Scaffold N50                  | 1891                          |
| Number of scaffolds           | 14                            |
| Total bases in scaffolds after filtering and trimming | 21,407                      |
| Scaffold N50 after filtering and trimming | 11,374                      |
| Number of scaffolds after filtering and trimming | 14                        |
| Number of scaffolds with RAST-annotated PEGs | 2                           |
| Number of PEGs                | 30                            |
### Table 2 Annotation of selected PEGs of putative orphan biosynthetic gene clusters

| Proposed functions of cluster elements | Scaffold | Start  | Stop  | PEG | RAST annotation | Best hit from PSI-BLAST | Query coverage % | E-value | Identity % | Accession number |
|----------------------------------------|----------|--------|-------|-----|------------------|-------------------------|-----------------|---------|-------------|-----------------|
| (a) 14-E7 selected PEGs annotation     |          |        |       |     |                  |                         |                 |         |             |                 |
| Regulatory gene                        | Scaffold_C361 | 395    | 1345  | 28  | Transcription initiation factor B | Transcription initiation factor IIIB [candidate division MSBL1 archaeon SCGC-AAA259014] | 95  | 3e−138    | 65  | gi|085656859|KXR9394.1 |
| Biosynthesis of specialized metabolite | Scaffold_C371 | 2077   | 3141  | 54  | Dolichol-phosphate mannosyltransferase (EC 2.4.1.83) homolog | Dolichol monophosphate mannosylsynthase [Chloroflexi bacterium CG28_land_8_20_14_0_20_45_12] | 99  | 9e−109    | 47  | gi|1277809164|PLU23225.1 |
|                                        | Scaffold_C383 | 437    | 1396  | 73  | Radical SAM domain protein | Radical SAM/SPASM domain-containing protein [Thermodesulfobium narugense] | 83  | 2e−18     | 28  | gi|503521935|WP_013756246.1 |
|                                        | Scaffold_16 | 18334  | 17825 | 202 | Geranylgeranyl diphosphate synthase (EC 2.5.1.29) | Hypothetical protein [candidate division MSBL1 archaeon SCGC-AAA259009] | 100 | 8e−80     | 75  | gi|085669946|KXR9017.1 |
| Subtilases                             | Scaffold_16 | 11832  | 13133 | 200 | Peptidase S8 and S53, subtilisin, kexin, sedolisin | Peptidase S8/S53 subtilisin kexin sedolisin [Halobacterium salinarum] | 37  | 1e−11     | 33  | gi|1118770207|SM81338.1 |
|                                        | Scaffold_3  | 3824   | 3937  | 232 | Hypothetical protein | Hypothetical protein [Thermoproteus vulgaris] | 82  | 8e−14     | 35  | gi|501769773|WP_012653463.1 |
| Resistance to specialized metabolite   | Scaffold_3  | 3169   | 3348  | 231 | Hypothetical protein | Hydropathy transporter permease [Desulfotobacterium sp. PCE1] | 86  | 0.076*    | 32  | gi|516886679|WP_019850372.1 |
|                                        | Scaffold_2  | 9816   | 8962  | 218 | NAD-dependent glyceraldehyde-3-phosphate dehydrogenase (EC 1.2.1.12) | Glyceraldehyde-3-phosphate dehydrogenase [candidate division MSBL1 archaeon SCGC-AAA25917] | 99  | 4e−166    | 83  | gi|085671588|KXR02384.1 |
|                                        | Scaffold_2  | 9970   | 9818  | 219 | NAD-dependent glyceraldehyde-3-phosphate dehydrogenase (EC 1.2.1.12) | Glyceraldehyde-3-phosphate dehydrogenase [candidate division MSBL1 archaeon SCGC-AAA25917] | 92  | 2e−18     | 89  | gi|085671588|KXR02384.1 |
| (b) 10-2G selected PEGs annotation     |          |        |       |     |                  |                         |                 |         |             |                 |
| Synthesis of non-ribosomal peptide     | Scaffold_7 | 29     | 160   | 20  | Hypothetical protein | Non-ribosomal peptide synthetase [Mycobacterium minnesota] | 67  | 0.18*    | 45  | gi|117850111|WP_083022343.1 |
Table 2 (continued)

| Proposed functions of cluster elements | Scaffold   | Start | Stop | PEG | RAST annotation                                      | Best hit from PSI-BLAST                                                                 | Query coverage % | E-value | Identity % | Accession number               |
|----------------------------------------|------------|-------|------|-----|------------------------------------------------------|----------------------------------------------------------------------------------------|------------------|---------|-------------|--------------------------------|
| Biosynthesis of specialized metabolite/peptide modification | Scaffold_7  | 3719  | 4762 | 29  | Glycosyltransferase                                  | Glycosyltransferase Family 4 protein [Enhydrobacter aerococcis]                        | 98               | 1e−30   | 28          | gi|1194598116 [WP_085933361.1    |
|                                        | Scaffold_3  | 202   | 702  | 3   | Hypothetical protein                                 | Class I SAM-dependent methyltransferase [Methanosarcina mazei]                        | 78               | 4e−12   | 34          | gi|850504616|WP_048046626.1                  |
|                                        | Scaffold_3  | 2297  | 2989 | 6   | Glycosyltransferase                                  | Glycosyltransferase [Parcubacteria group bacterium CGIT_big_fil_rev_8_21_14_0_20_39_14] | 77               | 5e−35   | 38          | gi|1277086632|PIQ92058.1                      |
| Resistance to specialized metabolite   | Scaffold_3  | 2961  | 3542 | 7   | Hypothetical protein                                 | ABC transporter permease [Hymenobacter sp. CRA2]                                       | 47               | 0.73    | 27          | gi|1150819492 [WP_078012825.1      |

Annotation of the putative biosynthetic gene cluster elements in: (a) 14-7E and (b) 10-2G. * PEGs with PSI-BLAST hits of E-value > 0.005. The proposed functions of the biosynthetic gene cluster elements are denoted, each function beside its relevant annotated gene. The scaffold number is denoted, as well as the start, stop and PEG number. RAST annotation for each gene is then denoted. Lastly, PSI-BLAST best hit for each gene is denoted, its query coverage, percentage identity and best hit accession number.
the Sea of Japan [39], the halophilic and thermophilic bacterium *Halothermothrix orenii* [40], and the thermophilic bacterium *Thermoanaerobacterium* sp. *PSU-2* [41]. Of note, 77 of the detected PSI-BLAST best hits to 14-7E PEGs aligned with archaeal sequences (Additional file 1: Table S1), e.g., candidate division MSBL1 archaeon SCGC-AAA261F19, candidate division MSBL1 archaeon SCGC-AAA385D11 (Table 2, Additional file 1: Table S1) [42]. Metagenome Analyzer (MEGAN) algorithm [43] predicted phylogenetic origins of the fosmid insert DNA in 14-7E and 10-2G as denoted in (Additional file 1: Table S3, Figure S4). Although most of the PEGs yielded no hits (261 out of 289 PEGs for 14-7E) and (27 out of 30 PEGs pertaining to 14-7E were assigned to Archaea.

**Annotation of putative orphan biosynthetic gene clusters**

Nine PEGs in 14-7E, putatively encoding specialized metabolite genes, were identified on six of the scaffolds and were further analyzed (Table 2a). Sequence maps of the putative orphan archaeal biosynthetic gene clusters identified in 14-7E (Fig. 4) had scaffolds harboring putative biosynthetic gene cluster elements, including: (1) a transcription initiation factor IIB on scaffold C361 (65% identity) (2) a dolichol monophosphate mannose synthase on scaffold C371 (47% identity) (3) a subtilase family protein (33% identity) and a geranylgeranyl diphasate synthase on scaffold 16, (4) a peptidase S8/S53 subtilisin kexin sedolisin (35% identity) and an ATP-binding cassette (ABC) transporter permease on scaffold 3 (32% identity), and lastly a (5) radical SAM/SPASM domain-containing protein (28% identity) on scaffold C383. Also, two putative NADH dehydrogenases were detected on 14-7E scaffolds as detected by the Antibiotic Resistant Target Seeker (ARTS) program (Table 2). It is likely that the former genes are part of a putative orphan archaeal biosynthetic gene cluster that includes a transcription initiation factor, two subtilases, a dolichol monophosphate mannose synthase, a geranylgeranyl diphasate synthase, resistance genes, and a radical SAM domain-containing protein.

Similarly, five PEGs in 10-2G, encoding for specialized metabolite genes, were identified on two of the scaffolds (Table 2b). Sequence maps of the putative orphan biosynthetic gene clusters on 10-2G (Fig. 5) have the following scaffolds harboring putative biosynthetic gene cluster elements: (1) a non-ribosomal peptide synthetase (NRPS) (45% identity) and a glycosyltransferase Family 4 protein (28% identity) on scaffold 7, (2) a class I SAM-dependent methyltransferase (34% identity), a glycosyl transferase (38% identity) and an ABC transporter permease (27% identity) on scaffold 3. Lastly, the search by ARTS tool did not yield putative resistance genes. It is likely that the former genes are part of a putative orphan biosynthetic gene cluster that includes a NRPS, two glycosyltransferases, a SAM-dependent methyl transferase and a resistance gene.

**Discussion**

**Antibacterial activity of Red Sea Atlantis II (ATII LCL) metagenomic library clones**

We screened a prokaryotic metagenomic library of the deepest, secluded and extreme Red Sea environment, the ATII LCL, for antibacterial and anticancer effects. Eleven positive clones (out of 10,656) were identified, and two (14-7E and 10-2G) were further sequenced (Fig. 2). In congruence, Yung et al. identified three clones from two prokaryotic metagenomic libraries associated with a green alga and a marine sponge, having collectively 106,500 clones [44]. It is possible that functional screening of metagenomic libraries, using *E. coli* as the host, gives an inherently low yield of positives [13, 45]. Difficulties in heterologous expression are estimated to prevent 60% or more of the enzymes from being natively expressed [13, 45]. Heterologous expression of foreign DNA is problematic mainly because of difficulties in translation or transcription and/or the lack of the precursors [13]. The use of more than one host may improve the heterologous expression of native proteins [13].

In the current study, we used *Bacillus* sp. Cc6 strain as the challenging strain, which is a marine *Bacillus* strain that inhabits an ecological niche relatively similar to the Red Sea and its antibiotic resistance is compatible with the fosmid vector [44]. Marine bacteria are well-known producers of specialized metabolites, that assist in their competitive survival, using mechanisms such as quorum quenching and antibiotic activity [10]. Earlier, two unique antibiotic resistance enzymes were detected in the same ecosystem (ATII LCL) [35]. Although microbes living in ATII LCL site were not subjected a priori to antibiotics, they might have developed competitive advantages for better survival, such as having antibiotic resistance genes [35, 46, 47]. Perhaps the interplay between antibiotic and antibiotic-resistance genes in ATII LCL has a role in the microbial community members’ survival and communication [46].

**Anticancer effects of selected Red Sea Atlantis II (ATII LCL) metagenomic library clones**

It is expensive and technically challenging to evaluate the anticancer effect for all the clones, as opposed to screening for antibiotic. By this approach, we aimed to investigate the antibacterial activity of the active clones more thoroughly, and then test for anticancer effect, due to the reason that many anticancer agents were originally
discovered by having an antibacterial effect [6]. Although both 14-7E and 10-2G were originally obtained from the same ATII LCL metagenome, they resulted into differential decrease in cell viability. The effect of the extracts on mammalian cell viability was tested on breast cancer (MCF-7), osteosarcoma (U2OS) and non-cancerous fibroblast (1BR hTERT) cell lines. This allowed us to compare the effect of the lysates on the viability of cancerous and non-cancerous cell lines.

Among the cancer cell lines, 10-2G extracts only decreased the cell viability of MCF-7 cells (42% ± 8.1 at 50% v/v concentration, P ≤ 0.05). 10-2G exhibited a selective decrease in cell viability of MCF-7 cells, since it did not significantly alter the cell viability of the non-cancerous cells and U2OS cells. On the other hand, 14-7E extracts decreased the cell viability of cancer and non-cancer cell lines at 50% v/v concentration as follows: MCF-7: 39.1% ± 6.6 (P ≤ 0.05), U2OS: 35.7% ± 1.9 (P ≤ 0.001) and 1BR hTERT: 48.1% ± 3.4 (P ≤ 0.05) (Fig. 3). Morphological features characteristic of cell death, were observed microscopically, when compared to control cells (Additional file 1: Figure S5). Since the detected genes were different in 14-7E and 10-2G, most likely different specialized metabolites/enzymes were possibly expressed and hence conferred differential decrease in mammalian cell viability (Table 2, Additional file 1: Tables S1, S2).

Although our cell viability assays were performed at different concentrations of extracts (i.e. 1, 5, 10, 15, 20 and 50%) (Additional file 1: Figure S3), significant differences were observed at the highest concentrations, and we therefore focus on the 50% v/v. Although 50%
v/v concentration might not be physiologically achievable for the lysate, it is likely that the active molecule is diluted in the cell lysate. Large fluctuations in standard deviation values were detected for the two lowest concentrations of 14-7E lysates (1%, 5% v/v). It is likely that such large standard deviations would be due to the cell lysate containing different lysate components and different dilutions of the active molecule, which was similarly reported in earlier studies [48]. Our results indicate that 10-2G lysate would be a better candidate to look for selective anticancer effect towards breast cancer cells. Moreover, the lack of 10-2G lysate activity against non-cancerous cells seems to be beneficial as it might prevent adverse effects. The mechanism of action of the enzymes/metabolites could be further investigated, especially with regards to MDR [3]. Also, the effects on other cancer cell lines could be further conducted.

A study by Sagar et al. tested the cytotoxic effects of extracts of marine strains inhabiting similar environments, which are brine–seawater interfaces of several of Red Sea brine pools, namely: Discovery Deep, Kebrit Deep, Nereus Deep and Erba Deep [27]. The brine–seawater interfaces are unique environments, but different from the extreme brine pools, and the Atlantis II brine pool anticancer effects were not studied [25, 27]. Moreover, Sagar and coworkers cultured the microbial strains then tested the cytotoxic effects of their lipophilic and hydrophilic extracts [27]. They also performed cultures and extraction on a larger scale (i.e., larger culture volume and 2 weeks duration) [27]. Our approach has an additional advantage of capturing bioactive enzymes from the major, uncultured portion of the metagenome [49].

Archaeal orphan biosynthetic gene cluster from ATII brine pool LCL on 14-7E

The selected clones were both sequenced by high-throughput sequencing platforms. We sequenced 201,086 bp in 14-7E scaffolds and 21,407 bp in 10-2G scaffolds. 14-7E was sequenced using HiSeq, while 10-2G was sequenced using MiSeq. Despite the different sequencing instruments, both sequencing approaches have similar chemistries. Additionally, similar de novo assembly methods and quality filtering were performed. Surprisingly, the number of retrieved sequences for 14-7E were larger than the expected size, and this could be attributed to the possibility that more than one fosmid insert was sequenced.

We detected gene clusters in the assembled sequences of fosmid 14-7E and considered them orphan gene clusters because the metabolites are yet to be characterized [8] (Fig. 4, Additional file 1: Figure S2). Using Sanger sequencing we confirmed one of the scaffolds (scaffold 2). The PSI-BLAST search results suggest an archaeal origin for these sequences because of the large number of hits with archaeal sequences (77 hits) (Table 2, Additional file 1: Table S1). Thirty-three PEGs had hits similar to the candidate division Mediterranean Sea Brine Lakes 1 (MSBL1) archaeon, pertaining to different single-cell amplified genomes [42]. MSBL1 is an uncultured lineage and the amplified genomes from this lineage were obtained from similar environments but not including ATII LCL (sites included: ATII upper convective layer, Discovery Deep brine, ATII brine-interface of 2036 m depth, Nereus brine and Erba brine water) [42].

Out of the 33 hits, 58% were hits with Discovery brine, 18% Atlantis II brine-interface of 2036 m depth, 15% Nereus brine and 9% Erba brine [42]. In agreement, MEGAN phylogenetic analysis corroborates the conclusion that 14-7E fosmid insert DNA is still largely metagenomic dark matter—as most of the PEGs were not assigned to particular taxa (261 out of 289 PEGs (Additional file 1: Table S3, Figure S4-a). Additionally, MEGAN phylogenetic results support the possible archaeal origin of 14-7E sequences, as eight PEGs were assigned to Archaea, one PEG was assigned to the class Halobacteria, one PEG was assigned to Methanococci class, and two PEGs were assigned to Methanomicrobia class. One PEG was assigned to each of the following species: Halovivax asiaticus [50]—an extremely halophilic sediment archaeon—, Methanococcus maripaludis [51]—a methanogenic sediment archaeon, Methanosarcina acetivorans [52]—a methanogenic marine sediment archaeon—and Methanosarcina soligelidi [53]—a methanogenic soil archaeon.

Putative components of a BGC were identified on the fosmid insert DNA of 14-7E. First, a transcription factor was detected (on contig 361) and annotated as transcription initiation factor IIβ, which is essentially required for archaeal transcription initiation [54]. One way to increase the ability of E. coli to express heterologous proteins in metagenomic libraries, is to express heterologous sigma factors [55]. Perhaps the presence of TFIIβ facilitated the heterologous expression of the putative archaeal genes, although E. coli was the host.

Two peptidases of the subtilase family were detected (on scaffold 3 and 16), which may have contributed to the observed antibacterial and anticancer effects. Amidases could be acting as antimicrobials that break the amide bonds in the cell walls [49]. Subtilisins have shown antibiofilm activity against several species, such as Listeria monocytogenes, Pseudomonas and Bacillus sp. [56]. In agreement with our results, subtilases are also reported to have potent anticancer effects, especially the catalytic subunit A (SubA), and researchers are aiming to improve their specificity to cancer cells [57].
Three PEGs were annotated as putative specialized metabolite biosynthetic genes: a geranylgeranyl diphosphate synthase (on scaffold 16), a dolichol monophosphate mannose synthase (on contig 371), and a radical SAM domain protein (on contig 383). Geranylgeranyl diphosphate synthase catalyzes the condensation of the 5-Carbon ring of geranylgeranyl diphosphate of some specialized metabolites e.g. carotenoids [58]. Dolichol monophosphate mannose synthase is an enzyme involved in glycosylation and was detected in Archaea before [59]. The putative biosynthetic genes hint at the possibility that carbon rings are perhaps being formed and that glycosylation of proteins might occur. Radical SAM enzymes are key players in the post-translational modification of ribosomally synthesized and post-translationally modified peptides (RiPPs) [60]. Several RiPPs have antibacterial and anticancer activities, rendering them an interesting group of specialized metabolites [60]. SAM enzymes catalyze a lot of different reactions such as: epimerization, C–C bond formation, thioether formation, complex rearrangements and methylation [60]. Particularly, class C SAM methylases have a role in the biosynthesis of specialized metabolites with antibacterial and anticancer effects e.g. fosfomycin [61]. Consequently, the detected radical SAM domain-containing protein points towards the possibility of its role in either biosynthesis of the specialized metabolite, or post-translational modification of a synthesized RiPP [60, 61].

Finally, a ‘self-defense’ gene was annotated to be coding for an ABC transporter permease (on scaffold 3). Resistance genes are frequently encoded within the specialized metabolism gene clusters to protect the host from the natural product it synthesizes [9, 62]. ABC transporters pump unwanted compounds outside the cell, e.g. toxins [63]. Perhaps the detected ABC permease is protecting the host having the putative specialized metabolism gene cluster. To the best of our knowledge, this could be the first report of a putative orphan archaeal biosynthetic gene cluster, harbored on 14-7E, resulting from functional screening of a Red Sea brine pool metagenome. A recent study, which included 29 genomes of archaeal species, detected 414 putative BGCs [64]. Earlier, an ectoine BGC was identified in the genome of the marine archaeon *Nitrospumilus maritimus* [65]. BGCs have been previously detected in archaeal genomes that code for a variety of molecules including terpenes, bacteriocins and NRPs [66]. In contrast to the aforementioned genomic mining studies, our study revealed an orphan archaeal BGC from a metagenomic sample. It is noteworthy that two putative NAD-dependent glyceraldehyde-3-phosphate dehydrogenases detected on scaffold 2 (Table 2), were also detected by ARTS pipeline [67]. A new strategy proved its success in characterizing the antibiotic thiotetronic acid BGC, by searching for duplicated housekeeping genes in close proximity to the BGCs [68]. Such duplicated housekeeping genes are playing protective roles to resist the action of the produced natural product on the host [67, 68]. This finding strengthens the approach to further prioritize 14-7E cluster for experimentation, as it is more likely to be producing a novel bioactive natural product. It is also likely that the duplicated housekeeping genes on 14-7E are contributing to the resistance towards the bio-active compound.

Similar studies identified putative hydrolases, serine proteases and amidases [44, 49]. In addition to subtilases, we also detected components of putative orphan biosynthetic gene clusters. Further experiments and computational analyses would attribute more specific functions to each gene in the cluster [20] (Figs. 4, 5, Additional file 1: Figure S1). However, our work paves the way for finding novel metabolites and their clusters, especially in Archaea, because of the scarcity of reports on their natural products and BGCs [23]. Several archaeocins were previously identified and a subset of them are encoded by gene clusters such as halocin C8 [69]. Significant hits with terpene, peptide, polyketide, saccharide and alkaloid classes are leads to the chemical nature of the specialized metabolite produced by 14-7E (Additional file 1: Table S4), which should be further investigated.

**Putative orphan biosynthetic gene cluster from ATII brine pool LCL on 10-2G**

Another orphan gene cluster was detected within 10-2G [8]. For that cluster, however, MEGAN phylogenetic analysis was not conclusive, as 27 out of 30 PEGs had no hits to certain taxa (Additional file 1: Table S3, Figure S4-b). Four biosynthetic genes were detected: a non-ribosomal peptide synthase (NRPS) (on contig 7), a class I SAM-dependent methyltransferase (on contig 3), a glycosyltransferase Family 4 protein (on contig 7) and a glycosyltransferase (on contig 3). NRPSs are reported to produce peptides, some of which exhibit antibiotic and/or anticancer effects e.g. bleomycin and daptomycin [70]. Non-ribosomal peptides are a major class of bioactive compounds, whether antimicrobial or anticancer agents. The detected NRPS hints that 10-2G might be producing a bioactive peptide. The detected class I SAM-dependent methyltransferase perhaps is contributing in the biosynthesis of the specialized metabolite encoded by the putative gene cluster [60, 61]. Furthermore, class I SAM-dependent methyltransferases have a potential for biotechnological applications [71]. Glycosyltransferases are frequent contributors to the biosynthesis of specialized metabolites, and bioinformatic tools aim to detect them in the search of specialized metabolism genes [12, 72].
Finally, a resistance gene was detected as an ABC transporter permease (on contig 3). The function of this gene product might be the efflux of the specialized metabolite so that the host is unharmed [9, 62, 63]. The significant hits pertained to alkaloid, polyketide, saccharide and peptide classes, and the chemical nature of the specialized metabolite should be further investigated (Additional file 1: Table S4).

Future studies will determine the chemical nature of the specialized metabolite or whether an enzyme is rather acting. Additionally, different methods may be attempted to extract the specialized metabolite, e.g. such as ethyl acetate extraction method which was used in similar studies [73]. Transposon mutagenesis may be used to further decipher the essential gene(s) behind the observed activity [8, 44, 49]. Additionally, a targeted knock-down approach can be used to pinpoint the particular gene(s) responsible for the observed activities based on the current predicted functions [74, 75].

Study limitations and future prospects

The metagenomic library phenotypic screening approach used in this study is a high-throughput method to search for specialized metabolites, yet it has limitations [13]: (i) biosynthetic genes are inherently scarce (<2% of bacterial genome); (ii) heterologous protein expression is a challenge; and (iii) the insert size (40 kb) is much smaller than the typical BGC size (up to >150 kb) [13]. The antibacterial overlay assay results did not distinguish whether the observed antibiosis was due to the activity of proteins/enzymes coded by the fosmid DNA, or rather due to specialized metabolites produced by BGCs within the fosmid DNA [49]. Similarly, the anticancer activity was determined by using whole cell lysates, which also contain both chemicals and proteins [76]. So, further experiments are needed to determine the chemical nature of the effective agent, i.e. whether it is an enzyme(s) or rather a chemical compound(s).

Conclusions

In conclusion, two clones from the metagenomic library of the largest Red Sea brine pool exhibited antibacterial and anticancer effects. Sequencing and annotation of selected inserts detected orphan biosynthetic gene clusters, with the specialized metabolites yet to be characterized [8]. Interestingly, 14-7E harbored a putative archaeal orphan biosynthetic gene cluster. One of the clusters (on 14-7E) is predicted to act by producing a specialized metabolite or by the action of subtilases [56]. The second cluster (on 10-2G) is predicted to act by producing a non-ribosomal peptide. The observed antibiosis and anticancer effects of the ATII metagenomic library corroborates the approach of bioprospecting extreme environments, as it could be one of many solutions to the currently emerging antibiotic and chemotherapeutic resistance [3, 77].

Methods

Metagenomic fosmid library screening for antibacterial activity

Water samples from the lower convective layer (LCL) of ATII Red Sea brine pool (21° 20.72′ N and 38° 04.59′ E) was previously collected in the 2010 KAUST/WHOI/HCMR expedition [33]. Environmental DNA was extracted from the 0.1 µm filter as previously described [78] (Fig. 1). The ATII LCL fosmid library was previously constructed using pCC2FOS vector with the Copy Control Fosmid Library Production Kit (Epicenter). The library contains 10,656 clones [33]. A fresh copy of the aforementioned fosmid library was prepared prior to the downstream assays and was further used.

An antimicrobial overlay assay, similar to that reported in literature [44, 79], was used to test for antibacterial activity. For the phenotypic assay, the challenging strain was a marine Bacillus strain associated with the Australian marine sponge Cymbastela concentrica—Bacillus sp. Cc6 (gift from Torsten Thomas, University of New South Wales), while the positive control strain was E. coli CBAA11, which produces the antibacterial tambjamine [44, 80]. E. coli clones containing the fosmid library were grown on LB plates supplemented with 0.01% arabinose and 12.5 µg/ml chloramphenicol, incubated overnight at 37 °C and for an additional night at 25 °C. Bacillus sp. Cc6 was cultured in 100 ml LB with chloramphenicol at 37 °C with shaking until OD600 0.5. The culture was diluted to 1:100 in top agar (7.5 g/l) and poured on the plates with the grown colonies [79]. The overlay plates were incubated overnight at 25 °C and observed for clear zones in the top layer [44].

Extract preparation

Overnight cultures (100 ml culture incubated at 37 °C with shaking) from the positive clones, previously supplemented with auto-induction solution and chloramphenicol, were centrifuged at 3500 rpm for 10 min. Afterwards, the cell pellets were re-suspended in 20 ml of 10 mM Tris–HCl pH 7. The extracts were sonicated on ice at 20% maximal amplitude for 370 s, with 10 s intervals without sonication (Branson 150D Ultrasonic Cell Disruptor with 3 mm diameter sonotrode). The extracts were finally filter-sterilized with 0.2 µm membrane filters (Corning) [76]. Protein concentrations of the extracts were determined by the Pierce™ bicinchoninic acid BCA protein assay kit (ThermoFisher).
Cell lines and culture conditions
Three cell lines were used for the cell viability assay: a human breast adenocarcinoma cell line (MCF-7) [81], an osteosarcoma cell line (U2OS) [82] (gift from Andreas Kakarougkas, University of Sussex) and skin fibroblast cells (wild-type and non-cancerous cells) immortalized with human telomerase reverse transcriptase (IBR hTERT) [83–85]. The cells were cultured in DMEM (Lonza, Germany), supplemented with 10% fetal bovine serum (Lonza, Germany) and 5% Penicillin–Streptomycin (Lonza, Germany). All cells were grown at 37 °C in an incubator supplied with 5% CO₂.

Cell viability assay
The initial seeding density was adjusted to 10⁴ cells/well and left overnight to adhere to the bottom of the 96-well plates (Greiner Bio-One, Germany). The old medium was discarded, and 100 µl of fresh medium containing different concentrations (0, 1, 5, 10, 15, 20 and 50%) of the extracts were added. The percentage of remaining viable cells was assessed by the MTT assay after 48 h of exposure to the extracts. First, the medium was replaced by 100 µl fresh media supplemented with 20 µl of 5 mg/ml MTT reagent (3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide, Serva, Germany). After 3 h of incubation, the medium was discarded and 100 µl DMSO (Sigma-Aldrich, USA) was added to solubilize the purple precipitates.

Negative control cells (A₅₉⁵ control) were supplemented with complete medium and a cell-free medium was used as the blank (A₅₉⁵ blank). Absorbance at 595 nm was measured in a SPECTROstar Nano microplate reader (BMG LabTech, Germany). The percentage of cell viability was calculated as follows:

\[
\text{Cell Viability} \% = \left( \frac{A_{595 \text{ sample}} - A_{595 \text{ blank}}}{A_{595 \text{ control}} - A_{595 \text{ blank}}} \right) \times 100
\]

An additional buffer control experiment was conducted, by adding buffer 50% v/v to each of the three tested cell lines. The data are presented as the average of at least three independent experiments. For pairwise comparisons between the values, one-way ANOVA test was conducted, followed by post hoc Tukey test. The shown P values represent the significant differences between the mean of each condition and the mean of the negative control cells with buffer concentration 50% v/v (& P ≤ 0.05, # P ≤ 0.01 and $ P ≤ 0.001$). The ANOVA, post hoc test and P value calculation were conducted using the R program version 3.3.1 (R Development Core Team 2016).

Sequencing and bioinformatics
Two clones (14-7E and 10-2G) were selected for fosmid DNA extraction followed by sequencing. Overnight cultures were supplemented with auto-inducer/chloramphenicol. Fosmid DNA was extracted by QiAprep Spin Miniprep Kit (Qiagen). The 14-7E fosmid DNA was sequenced by the Illumina HiSeq 2000 100 bp paired-end read platform (Macrogen, Republic of Korea), while 10-2G fosmid DNA was sequenced by the Illumina MiSeq V3 300 bp paired-end read platform (I.GC, Germany). After sequencing and quality filtering, the reads were assembled by the de novo assembly programs SOAPdenovo2 [86] and the CLC Genomics Workbench v 8.0 assembler (Qiagen), respectively (Table 1).

Prior to annotation, the vector sequences (pCC2FOS™) were trimmed from the resulting scaffolds. E. coli sequence reads were also filtered out. E. coli NC_010473 DH10B served as the reference sequence, because the EPI300™-T1R Phage T1-resistant E. coli strain, derived from E. coli DH10B, was used for the fosmid library construction. Putative PEGs were determined in the resulting scaffolds with the RAST platform [87]. Each PEG was further compared to sequences in the publicly available databases by PSI-BLAST [37]. The PEGs were also compared to the protein sequences curated in the MIBiG database by BLASTX [38]. Phylogenic origins of the PEGs of 14-7E and 10-2G fosmid insert DNA were predicted by MEGAN algorithm by using BLASTX results against nr database and using default parameters [43]. Lastly, the scaffold sequences were screened for resistance genes including housekeeping genes that are duplicated within BGCs. The search for putative resistance genes was conducted by using ARTS tool [67].

Additional file

**Additional file 1: Figure S1.** Anti-bacterial overlay assay results on 96-well plates. Zones of inhibition of 14-7E (a), 10-2G (b1) and E. coli CBAA11 (positive control) (b2), against Bacillus sp. Cc6. A single petri dish contained 96 clones. **Figure S2.** Sequence maps of all the putative PEGs on 14-7E insert. Dark blue: regulatory genes, purple: resistance genes, pink: NRPSs and PKSs, Green: transferases and synthases, orange: hydrolases and peptides, dark red: Endonucleases, blue: ORFs with significant hits, grey: ORFs with non-significant hits yellow: trNA-Met-CAT and magenta: radical SAM domain proteins and class I SAM-dependent methyltransferases. **Figure S3.** Cell viability percentage of cell lines after exposure to selected whole cell lysates. (A) MCF-7 cells, (B) UOOS cells, and (C) 1BR hTERT cells, after 48 h exposure to extracts of: 14-7E (red) and 10-2G (green). Also presented are the media controls (dark blue) and 50% v/v buffer controls (light blue). The x-axis indicates the concentrations of the whole cell extracts (%v/v). The presented data for each condition is the mean of at least three independent experiments. P values are denoted as follows: $ P ≤ 0.05$, $ P ≤ 0.01$ and $ P ≤ 0.001$. **Figure S4.** Phylogenic trees as predicted by MEGAN for the insert DNA of (a) 14-7E and (b) 10-2G. **Figure S5.** Representative photos of MCF-7 (A) and 1BR hTERT (B) cells after exposure to 14-7E lysates for 48 h (200x magnification).
Abbreviations
ABC: ATP-binding cassette; antiSMASH: antibiotics and secondary metabolite analysis shell; ARTS: Antibiotic Resistant Target Seeker; ATL: Atlantis II Deep; BGCs: biosynthetic gene clusters; DHAs: deep hyparsaline anoxic basins; LCL: lower convective layer; MDR: multi-drug resistance; MBiG: Minimum Information about a Biosynthetic Gene cluster; MEGAN: Metagenome Analyzer; MRSA: methicillin-resistant Staphylococcus aureus; MSBL1: Mediterranean Sea Brine Lakes 1; NRP: non-ribosomal peptide synthetase; PEG: protein-encoding gene; RAST: Rapid Annotations using Subsystems Technology; RIPP: ribosomally synthesized and post-translationally modified peptide; SAM: S-adenosyl-methionine; SubA: subunit A.

Authors' contributions
LZ and RS designed the experiments. LZ and AAS conducted the fosmid library phenotypic screening assay and whole cell lysate preparation. LZ conducted the cell viability assays and BGC annotation. AO has supported the experiments. RKA has performed the bioinformatics data analysis. MG and PN have analyzed the data. RS has supervised this work. LZ, RS wrote the manuscript. LZ, MG, RKA, PN and RS have edited the manuscript, discussed the results and commented on the manuscript. All authors read and approved the manuscript.

Author details
1 Graduate Program of Biotechnology, School of Sciences and Engineering, The American University in Cairo, New Cairo, Cairo 11835, Egypt. 2 Department of Biology, School of Sciences and Engineering, The American University in Cairo, SSE (Parcel 7), Second Floor, Office: Room 2194, AUC Avenue, New Cairo, Cairo 11835, Egypt. 3 Chair of Bioprocess Engineering, Department of Biotechnology, Technische Universität Berlin, Ackerstrasse 76, ACK24, 13355 Berlin, Germany. 4 Department of Microbiology and Immunology, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt.

Acknowledgements
We would like to thank Torsten Thomas (University of New South Wales) for providing us with the strains for the overlay assay. Many thanks to Andreas Kakarougkas (University of Sussex) for providing us with U2OS cells. We acknowledge the efforts of all the scientists and crew who contributed in KAUST Red Sea Expedition in spring 2010 and 2012, especially Drs. Abdulaziz Al-Suwailem and Andre Antunes (chief scientists). The authors also thank Dr. Ahmed Abdelaziz of the American University in Cairo for the DNA preparation work.

Competing interests
The authors declare that they have no competing interests.

Availability of data and materials
The datasets of generated and analysed during the current study, comprising 1854:1019–37.

Consent for publication
Not applicable.

Ethics approval and consent to participate
Not applicable.

Funding
This work was funded by the student research grant from the American University in Cairo, Egypt. LZ was supported by an EMBO short-term research fellowship.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 18 September 2018 Accepted: 6 March 2019 Published online: 18 March 2019

References
1. Brown ED, Wright GD: Antibacterial drug discovery in the resistance era. Nature. 2016;539:336–43.
2. Liu YY, Wang Y, Walsh TR, Yi LX, Zhang R, Spencer J, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis. 2016;16:161–8.
3. Long S, Sousa E, Kijoo A, Pinto MMM. Marine natural products as models to circumvent multidrug resistance. Molecules. 2016;21:892.
4. Newman DJ, Craig GM. Natural products as sources of new drugs from 1981 to 2014. J Nat Prod. 2016;79:629–61.
5. Walsh CT, Fischbach MA. Natural products version 20: connecting genes to molecules. J Am Chem Soc. 2010;32:2469–93.
6. Saiedia S, Hamzeloob-Moghadam M. Antibiotics against cancer. In: Saedina S, editor. New approaches to nat anticancer drugs. SpringerBriefs in pharmaceutical science & drug development. Berlin: Springer International Publishing, 2015.
7. Demain AL, Vaishnav P. Natural products for cancer chemotherapy. Microbiol Biotechnol. 2011;4:687–99.
8. Chiang Y-M, Chang S-L, Oakley BR, Wang CCC. Recent advances in awakening silent biosynthetic gene clusters and linking orphan clusters to natural products in microorganisms. Curr Opin Chem Biol. 2011;15:137–43.
9. Jensen PR. Natural products and the gene cluster revolution. Trends Microbiol. 2016;24:968–77.
10. Wietz M, Duncan K, Patin NV, Jensen PR. Antagonistic interactions mediated by marine bacteria: the role of small molecules. J Chem Ecol. 2013;39:879–91.
11. Ziemert N, Alanjary M, Weber T. The evolution of genome mining in microbes—a review. Nat Prod Rep. 2016;33:988–1005.
12. Blin K, Wolf T, Chevrete MG, Lu X, Schwalen CJ, Kaatsar SA, et al. antiSMASH 4.0—improvements in chemistry prediction and gene cluster boundary identification. Nucleic Acids Res. 2017;1854:1019–37.
13. Milshetyn A, Schneider JSS, Brady SFF. Mining the metabioome: identifying novel natural products from microbial communities. Chem Biol. 2014;21:1211–23.
14. Giddings L-A, Newman DJ. Bioactive compounds from marine extremophiles. Cham: Springer, 2015. p. 1–124.
15. Hug J, Bader C, Remtlikar M, Cernik K, Muller R. Concepts and methods to access novel antibiotics from actinomycetes. Antibiotics. 2018;7:44.
16. Eom SH, Kim YM, Kim SK. Marine bacteria: potential sources for compounds to overcome antibiotic resistance. Appl Microbiol Biotechnol. 2013;97:4763–73.
17. Shin HJ, Lee HS, Lee DS. The synergistic antibacterial activity of 1-acetyl-carboline and -lactams against methicillin-resistant Staphylococcus aureus (MRSA). J Microbiol Biotechnol. 2010;20:501–5.
18. Nikolouli K, Miosos D. Bioactive compounds synthesized by non-ribosomal peptide synthetases and type-I polyketide synthases discovered through genome-mining and metagenomics. Biotechnol Lett. 2012;34:1393–403.
19. Udvariaw DIW, Zeigler L, Assolkar RN, Singan V, Lapidus A, Fenical W, et al. Genome sequencing reveals complex secondary metabolome in the marine actinomycete Salinispora tropica. PNAS. 2007;104:10376–81.
20. Eustaquio AS, Nam SJ, Penn K, Lechner A, Wilson MC, Fenical W, et al. The discovery of salinosporamide K from the marine bacterium "Salinispora pacifica" by genome mining gives insight into pathway evolution. ChemBioChem. 2011;12:621–4.
21. Skropepa D, Wei L. Recent advances in deep-sea natural products. Nat Prod Rep. 2014;31:999–1025.
22. Hofmann C, Schneider K, Brunten C, Iiran E, Nicholson G, Bull AT, et al. Caboxamycin, a new antibiotic of the benzoxazole family produced by the deep-sea strain Streptomyces sp. NTK 937. J Antibiot. 2009;62:99–104.
23. Skropepa D. Deep-sea natural products. Nat Prod Rep. 2008;25:1131.
24. Nadeem F, Oves M, Qari H, Ismail I. Red sea microbial diversity for antimicrobial and anticancer agents. J Mol Biomark Diagn. 2015;07:1–14.
25. Antunes A, Ngugi DK, Stengl U. Microbiology of the Red Sea (and other) deep-sea anoxic brine lakes. Environ Microbiol Rep. 2011;3:416–33.
26. Hartmann M, Scholten JCC, Stoffers P, Wehrer F. Hydrographic structure of brine-filled deeps in the Red Sea—new results from the Shaban, Kebrt, Atlantis II, and discovery deep. Mar Geol. 1998;144:311–30.
27. Sagar S, Esau L, Hikmawan T, Antunes A, Holtermann K, Stengl U, et al. Cytotoxic and apoptotic evaluations of marine bacteria isolated from
brine–seawater interface of the Red Sea. BMC Complement Altern Med. 2013;13:1–8.
28. Sagur S, Esaù L, Holtermann K, Hikmatwan T, Zhang G, Stingl U, et al. Induction of apoptosis in cancer cell lines by the Red Sea brine pool bacterial extracts. BMC Complement Altern Med. 2013;13:344.
29. Faber E, Botz R, Poggenburg J, Schmidt M, Stoffers P, Hartmann M. Methane in Red Sea brines. Org Geochem. 1998;29:363–79.
30. Backer H, Schoell M. New deeps with brines and metalliferous sediments in the Red Sea. Nat Phys Sci. 1972;240:153.
31. Anschutz P, Blanc G, Monnin C, Boulegue J. Geochemical dynamics of the Atlantis II Deep (Red Sea): II. Composition of metalliferous sediment pore waters. Geochem Cosmochim Acta. 2000;64:3995–4006.
32. Abdallah RZ, Adel M, Ouf A, Sayed A, Ghazy MA, Alam I, et al. Aerobic methanotrophic communities at the Red Sea brine–seawater interface. Front Microbiol. 2014;5:487. https://doi.org/10.3389/fmirc.2014.00487.
33. Mohamed Y, Ghazy MA, Sayed A, Ouf A, El-Dorry H, Siam R. Isolation and characterization of a heavy metal-resistant, thermophilic esterase from a Red Sea Brine Pool. Sci Rep. 2013;3:1–8.
34. Sonbol SA, Ferreira ASJ, Siam R. Red Sea Atlantis II brine pool nitratilise with unique thermotolerance profile and heavy metal tolerance. BMC Biotechnol. 2016;16:14.
35. Elbehery AHA, Leak DJ, Siam R. Novel thermostable antibiotic resistance enzymes from the Atlantis II Deep Red Sea brine pool. Microb Biotechnol. 2017;10:189–202.
36. Ziko L, Adel M, Siam R. Red Sea brine pool specialized metabolism gene clusters encode potential metabolites for biotechnological applications and extremophile survival. Manusc. Subm. Publ. 2018.
37. Altschul SF, Madden TL, Schäffer AA, Zhang J, Zhang Z, Miller W, et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 1997;25:3389–402.
38. Mwirichia R, Alam I, Rashid M, Vinu M, Ba-Alawi W, Anthony Kamau A, et al. GRP78‑targeting subtilase cytotoxin sensitizes cancer cells to photodynamic therapy. Cell Death Dis. 2013;4:e741.
39. Medema MH, Kottmann R, Yilmaz P, Cummings M, Biggins JB, Blin K, et al. The Minimum information about a biosynthetic gene cluster (MIBGC) specification. Nat Chem Biol. 2015;11:625–31.
40. Nedashkovskaya OI, Vancanneyt M, Christiaens L, Kalinovskaya NI, Mikhailov VV, Swings J, et al. Aquimarina intermedia sp. nov., reclassification of Stenarivella latericola (Leewin 1969) as Aquimarina latericola comb. nov. and Gaetbulimicrobium brevitae Yoon et al. 2006 as Aquimarina brevitae comb. nov. and amended description of the genus Aquimarina. Int J Syst Evol Microbiol. 2006;56(5):2037–41.
41. Mavromatis K, Ivanova N, Anderson I, Lykidis A, Hooper SD, Sun H, et al. Genome analysis of the anaerobic thermophilic bacterium Halothermothrix orenii. PLoS ONE. 2009;4:e4192.
42. Sompong O, Khongkiang P, Mamimin C, Singkhala A, Prasertsan P, Birke M, et al. Genomic analysis of the actinomycetes. Nat Prod Rep. 2009;26:1362–84.
43. Walker CB, de la Torre JR, Klotz MG, Urakawa H, Pinel N, Arp DJ, et al. GRP78‑targeting subtilase cytotoxin sensitizes cancer cells to photodynamic therapy. Cell Death Dis. 2013;4:e741.
44. Tang X, Li J, Millán‑Aguiñaga N, Zhang JJ, O'Neill EC, Ugalde JA, et al. Nitrosopumilus maritimus genome reveals unique mechanisms for nitrification and autotrophy in globally distributed marine crenarchaeota. Proc Natl Acad Sci. 2010;107:8818–23.
45. Wang S, Lu Z. Secondary metabolites in archaea and extreme environments. In: Witzany G, editor. Biocommunication of archaea. Berlin: Springer International Publishing AG; 2017. p. 1–324.
46. Alanya M, Krumbholz B, Adamek M, Blin K, Weber T, Huson D, et al. The Antibiotic Resistant Target Seeker (ARTS), an exploration engine for antibiotic cluster prioritization and novel drug target discovery. Nucleic Acids Res. 2017;45:W42–8.
47. Tang X, Li J, Millán‑Aguiñaga N, Zhang J, O'Neill EC, Ugalde JA, et al. Identification of the tetroneric acid antibiotic biosynthetic pathways by target‑directed genome mining. ACS Chem Biol. 2015;10:2841–9.
48. Besser E, Peduzzi J, Rebiffat S, Carré‑Mlouka A. Antibacterial peptides and proteins in the face of extremes: Lessons from archaeaocins. Biochimie. 2015;118:1–12.
49. Agrawal S, Acharya D, Adholaia Y, Barrow CJ, Deshmukh SK. Non‑bacterial peptides from marine microbes and their antimicrobial and anticaner potential. Front Pharmacol. 2017;8:11–26.
50. Bush AW, Thompson ML, Wong LS, Micklefield J. S‑adenosyl‑methionine‑dependent methyltransferases: highly versatile enzymes in biocatalysis, biosynthesis and other biotechnological applications. ChemBioChem. 2012;13:2642–55.
51. Elbehery AHA, Leak DJ, Siam R. Characterization of Methanococcus maripaludis sp. nov., a new methanogen isolated from salt marsh sediment. Arch Microbiol. 1983;135:91–7.
52. Sowers KR, Baron SF, Ferry JG. Methanosarcina acetivorans sp. nov., an acetotrophic methane‑producing bacterium isolated from marine sediments. Appl Environ Microbiol. 1984;47:971–8.
53. Wagner D, Schirmack J, Ganzert L, Morozova D, Mangelsdorf K. Methanosarcina soligida sp. nov., a desiccation and freeze‑thaw‑resistant methanogenic archaeon from a Siberian permafrost‑affected soil. Int J Syst Evol Microbiol. 2013;63:2986–91.
54. Gehring AM, Walker JE, Santangelo TJ. Transcription regulation in archaea. J Bacteriol. 2016;198:1906–17.
55. Gaida SM, Sandovalo M, Nicolaou SA, Chen Y, Venkataramanan KP. Papoutsakis ET. Expression of heterologous sigma factors enables functional screening of metagenomic and heterologous genomic libraries. Nat Commun. 2015;6:1–10.
56. Thallinger B, Prasetyo EN, Nyanhongo GS, Guebitz GM. Antimicrobial enzymes: an emerging strategy to fight microbes and microbial bioslips. Biotechnol J. 2013;8:97–109.
57. Finczik M, Gabrìayia M, Baraniakiewicz J, Domagała A, Nowis D, Kujawa AM, et al. GRP78‑targeting subtilase cytotoxin sensitizes cancer cells to photodynamic therapy. Cell Death Dis. 2013;4:e741.
58. Liu C, Sun Z, Shen S, Lin L, Li T, Tan B, et al. Identification and characterization of the geranylgeranyl diphosphate synthase in Deinococcus radiodurans. Lett Appl Microbiol. 2014;58:219–24.
59. Urushibata Y, Ebisu S, Matsui S. I. A thermostable dolichol phosphoryl mannosyl synthase responsible for glycoconjugate synthesis of the hyperthermophilic archaeon Pyrococcus horikoshii. Extremophiles. 2008;12:665–73.
60. Benjida A, Balcy C, Berteau O. Radical SAM enzymes in the biosynthesis of ribosomally synthesized and post‑translationally modified peptides (RiPPs). Front Chem. 2017;5:1–13.
61. Bauerle MR, Schwanl EM, Booker SJ. Mechanistic diversity of radical S‑adenosylmethionine (SAM)‑dependent methylation. J Biol Chem. 2015;290:3995–4002.
62. Nett M, Ikeda H, Moore BS. Genomic basis for natural product biosynthetic diversity in the actinomycetes. Nat Prod Rep. 2009;26:1362–84.
73. Rajan BM, Kannabiran K. Extraction and identification of antibacterial secondary metabolites from marine Streptomyces sp. VITBRK2. Int J Mol Cell Med. 2014;3:130–7.
74. Tong Y, Churuanti P, Zhang L, Weber T, Lee SY. CRISPR-Cas9 based engineering of actinomycetal genomes. ACS Synth Biol. 2015;4:1020–9.
75. Peters JM, Colavin A, Shi H, Czarny TL, Larson MH, Wong S, et al. A comprehensive, CRISPR-based functional analysis of essential genes in bacteria. Cell. 2016;165:1493–506.
76. Felczykowska A, Dydecka A, Tomasz G, Sobo M, Kobos J, Bloch S, et al. The use of fosmid metagenomic libraries in preliminary screening for various biological activities. Microb Cell Fact. 2014;13:10S.
77. Williams DN. Antimicrobial resistance: are we at the dawn of the post-antibiotic era? J R Coll Physicians Edinb. 2016;46:150–6.
78. Rusch DB, Halpern AL, Sutton G, Heidelberg KB, Williamson S, Yooseph S, et al. The Sorcerer II Global Ocean Sampling expedition: northwest Atlantic through eastern tropical Pacific. PLoS Biol. 2007;5:e77.
79. Brady SF. Construction of soil environmental DNA cosmid libraries and screening for clones that produce biologically active small molecules. Nat Protoc. 2007;2:1297–305.
80. Burke C, Thomas T, Egan S, Kjelleberg S. The use of functional genomics for the identification of a gene cluster encoding for the biosynthesis of an antifungal tambjamine in the marine bacterium Pseudoalteromonas tunicata: brief report. Environ Microbiol. 2007;9:814–8.
81. Soule HD, Vazquez J, Long A, Albert S, Brennan M. A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst. 1973;51:1409–16.
82. Heldin CH, Johnson A, Wenner gren S, Wernstedt C, Betsholtz C, Westermark B. A human osteosarcoma cell line secretes a growth factor structurally related to a homodimer of PDGF A-chains. Nature. 1986;319:511–4.
83. Auclair Y, Rouget R, Affar EB, Drobetsky EA. ATR kinase is required for global genomic nucleotide excision repair exclusively during S phase in human cells. PNAS. 2008;105:17896–901.
84. Brunton H, Goodarzi AA, Noon AT, Shrikhande A, Hansen RS, Jeggo PA, et al. Analysis of human syndromes with disordered chromatin reveals the impact of heterochromatin on the efficacy of ATM-dependent G2/M checkpoint arrest. Mol Cell Biol. 2011;31:4022–35.
85. Fujisawa H, Nakajima NI, Sunada S, Lee Y, Hirakawa H, Yajima H, et al. VE-821, an ATR inhibitor, causes radiosensitization in human tumor cells irradiated with high LET radiation. Radiat Oncol. 2015;10:175.
86. Luo R, Liu B, Xie Y, Li Z, Huang W, Yuan J, et al. SOAPdenovo2: an empirically improved memory-efficient sort de novo assembler. Gigascience. 2012;1:1–6.
87. Aziz RK, Bartels D, Best A, DeJongh M, Disz T, Edwards RA, et al. The RAST server: rapid annotations using subsystems technology. BMC Genomics. 2008;9:75.